Management of Hepatitis C Infection

  • Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
  • Editor In Chief: Stefan Zeuzem, MD
  • Last Reviewed: 7/24/18 (What's New)

Summary

  • Efficacy of HCV treatment varies by HCV genotype and fibrosis stage
  • Some newer DAAs have activity against multiple or all genotypes
  • Ledipasvir/Sofosbuvir
    • All 3 phase III ION trials demonstrated high SVR rates with  ledipasvir/sofosbuvir with or without ribavirin when administrated for 8, 12, or 24 weeks in patients with genotype 1 HCV infection
      Sofosbuvir/Velpatasvir
        Sofosbuvir/Velpatasvir/Voxilaprevir
          Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir
            Daclatasvir
              Elbasvir/Grazoprevir
                Glecaprevir/Pibrentasvir
                  Direct-Acting Antivirals in Cirrhotic Patients
                    Ledipasvir/Sofosbuvir
                      Sofosbuvir/Velpatasvir
                        Sofosbuvir/Velpatasvir/Voxilaprevir
                          Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir
                            Elbasvir/Grazoprevir
                              Glecaprevir/Pibrentasvir

                            Action required